Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta's Setback Deepens With Another Gene Therapy Fatality
11:43am, Friday, 18'th Jul 2025
Sarepta Therapeutics SRPT shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company'
Sarepta shares sink on third gene therapy-linked death
10:39am, Friday, 18'th Jul 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares pulled back after Thursday's gains on the announcement of a third patient death linked to the company's experimental gene therapies. The patient, who was
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders
08:45am, Friday, 18'th Jul 2025
NEW YORK , July 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS
Sarepta Stock Plummets 23%. Here's Why.
08:17am, Friday, 18'th Jul 2025
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after two teenage boys receiving the treatment died earlier this year.
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
08:12am, Friday, 18'th Jul 2025
LOS ANGELES, July 18, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“S
SAN DIEGO , July 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 2
Sarepta shares slump after report of patient death in early-stage study
05:37am, Friday, 18'th Jul 2025
Shares of Sarepta Therapeutics declined 16.5% to $18.32 in premarket trading on Friday after a Bloomberg report that a patient enrolled in an early-stage study of one of the company's gene therapies h
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
06:06pm, Thursday, 17'th Jul 2025
NEW YORK , July 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and J
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
12:10pm, Thursday, 17'th Jul 2025
Sarepta Therapeutics, Inc. SRPT stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevidys, its approved gene therapy for Duchen
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
12:01pm, Thursday, 17'th Jul 2025
Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.
Sarepta shares soar on restructuring, R&D refocus
11:49am, Thursday, 17'th Jul 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped on a sweeping restructuring plan that includes cutting about 500 jobs, or 36% of its workforce, in a move aimed at reducing annual operating expens
Biotech Stock Soars on Restructuring Plan, Layoffs
10:37am, Thursday, 17'th Jul 2025
Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance.
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investo
